Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas
Authors
Keywords
Meningioma, Skull base, Gene mutation, Immune checkpoint inhibitors
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 144, Issue 1, Pages 11-20
Publisher
Springer Science and Business Media LLC
Online
2019-06-09
DOI
10.1007/s11060-019-03198-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors
- (2018) Anthony R. Guastella et al. JOURNAL OF NEURO-ONCOLOGY
- PD-L1 expression in meningiomas
- (2018) Mahlon D. Johnson JOURNAL OF CLINICAL NEUROSCIENCE
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma
- (2018) Dustin Proctor et al. OncoImmunology
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- (2017) Lieve Brochez et al. EUROPEAN JOURNAL OF CANCER
- PD-1 and cancer: molecular mechanisms and polymorphisms
- (2017) Arash Salmaninejad et al. IMMUNOGENETICS
- The Emerging Role of TRAF7 in Tumor Development
- (2017) Tiziana Zotti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas
- (2017) Matthew R. Strickland et al. JOURNAL OF NEUROSURGERY
- Targeting TDO in cancer immunotherapy
- (2017) Cheng-Peng Yu et al. MEDICAL ONCOLOGY
- Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence
- (2017) Ümmügülsüm Yesilöz et al. NEURO-ONCOLOGY
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Next generation predictive biomarkers for immune checkpoint inhibition
- (2016) Yulian Khagi et al. CANCER AND METASTASIS REVIEWS
- Altered tryptophan metabolism in human meningioma
- (2016) Noble Kumar Talari et al. JOURNAL OF NEURO-ONCOLOGY
- Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma
- (2016) Seunggu J. Han et al. JOURNAL OF NEURO-ONCOLOGY
- TDO as a therapeutic target in brain diseases
- (2016) Cheng-Peng Yu et al. METABOLIC BRAIN DISEASE
- Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
- (2015) Leland Rogers et al. JOURNAL OF NEUROSURGERY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
- (2015) Kim C. Ohaegbulam et al. TRENDS IN MOLECULAR MEDICINE
- Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
- (2015) Ziming Du et al. Oncotarget
- Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
- (2015) Yong Feng et al. Oncotarget
- Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology
- (2014) Seray Adams et al. PLoS One
- Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases
- (2013) Jan Frederick Cornelius et al. ACTA NEUROCHIRURGICA
- Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations
- (2013) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1
- (2013) Ian M. Zitron et al. CANCER BIOLOGY & THERAPY
- Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
- (2013) Priscilla K Brastianos et al. NATURE GENETICS
- Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
- (2013) V. E. Clark et al. SCIENCE
- IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
- (2012) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation
- (2012) Lucas Leite Cunha et al. ENDOCRINE-RELATED CANCER
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- The Paradigm of Skull Base Meningiomas: What Is Optimal?
- (2011) Basant Kumar Misra World Neurosurgery
- The role of radical microsurgical resection in multimodal treatment for skull base meningioma
- (2010) Tsutomu Ichinose et al. JOURNAL OF NEUROSURGERY
- Comparative Protein Profiling Reveals Minichromosome Maintenance (MCM) Proteins As Novel Potential Tumor Markers for Meningiomas
- (2009) Okay Saydam et al. JOURNAL OF PROTEOME RESEARCH
- Recurrence and Outcome in Skull Base Meningiomas: Do They Differ from Other Intracranial Meningiomas?
- (2008) Anil Nanda et al. SKULL BASE-AN INTERDISCIPLINARY APPROACH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now